Klineo, an e-health start-up created in 2021, is deploying a platform to democratize access to clinical trials. On April 29, it announced a fundraising of 2 million euros. The round table was conducted with Bpifrance, with the support of business angels.
A platform with two interfaces, for patients and doctors
The start-up's objective is to allow patients to easily find clinical trials, adapted to the patient's situation and geographically close to where they live. “To find a clinical trial, the information is today very complex to search on public sites”, notes Thomas Peyresblanques, CEO of Klineo. The young company claims that more than 70% of cancer patients would be ready to participate in clinical trials if they were aware of their existence, while only 5% of them ultimately join these trials.
Advertisement
The start-up, founded by two engineers from École Polytechnique and an oncologist from the Gustave-Roussy Institute, is developing a platform with two interfaces, for patients and for doctors. In both cases, a form to find out the patient's criteria is requested.
“Once these criteria are met, we get a results page, explains Thomas Peyresblances. We have built algorithms that best match the criteria necessary to enter a clinical trial”. These algorithms based on artificial intelligence are used to structure the data, with those on the criteria being written in free text.
Over 1000 users claimed
The patient can share his results with his referring oncologist. If the latter considers the trials relevant, he can make a request on the platform to the doctor responsible for the trial, who validates the inclusion consultation or not. “Conversely, the doctor responsible for the trial does not have access to the patient database”, notes the CEO of Klineo. The platform is free for doctors and patients. To function, the start-up forms partnerships with those who finance the trials, whether industrial (PfizerAstraZeneca, Pierre Fabre) or academic (Unicancer, Lysarc).
The platform developed by Klineo was officially launched in January 2023. A pilot project had been carried out the previous year for triple negative breast cancer, in collaboration with a patient association. The solution was then deployed for all breast cancers, for skin cancers and lymphomas. The start-up now boasts more than 1,000 users, both patients and doctors, with more than 200 centers in France in which at least one professional uses the platform.
Advertisement
Cover all types of cancer
With this new funding, Klineo intends to expand to other pathologies. “We are going to expand to lung cancer very soon, says Thomas Peyresblances. By the end of the year, the goal is to have all cancer types, both solid oncology and hematology, available for the platform.”
In the longer term, the start-up wants to deploy its platform in Europe, with clinical trials often open in several countries at the same time, and then conquer the American market. It also recruited technical profiles, to increase from 11 to 15 employees.
Selected for you